Produktbeschreibung
Released during platelet aggregation. Neutralizes the anticoagulant effect of heparin because it binds more strongly to heparin than to the chondroitin-4-sulfate chains of the carrier molecule. Chemotactic for neutrophils and monocytes. Inhibits endothelial cell proliferation, the short form is a more potent inhibitor than the longer form. {ECO:0000269|PubMed:7644496}. Biological Activity: Fully biologically active when compared to standard. The biological activity determined by a chemotaxis bioassay using human fibroblasts is in a concentration of 1.0-10ng/ml. Sequence: EAEEDGDLQC LCVKTTSQVR PRHITSLEVI KAGPHCPTAQ LIATLKNGRK ICLDLQAPLY KKIIKKLLES Molecular Weight: 7.8kD PubMed ID: 3098319, 1695112, 11468158, 15815621, 15489334, 893407, 267922, 601757, 6445090, 7644496, 23536183, 8031770, 7547867 Gene Name: PF4,CXCL4,SCYB4 Swiss Prot: P02776 Storage and Stability: Lyophilized powder may be stored at -20C. Stable for 12 months at -20C. Reconstitute with sterile PBS. Aliquot to avoid repeated freezing and thawing. Store at -20C. Reconstituted product is stable for 12 months at -20C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
* MwSt. und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
